• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • TB
    • View Item
    Jan 22, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Introducing new and repurposed TB drugs: the endTB experience

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Seung et al 2020 Introducing new ...
    Size:
    233.8Kb
    Format:
    PDF
    Download
    Authors
    Seung, KJ
    Khan, U
    Varaine, F
    Ahmed, S
    Bastard, M
    Cloez, S
    Damtew, D
    Franke, MF
    Herboczek, K
    Huerga, H
    Islam, S
    Karakozian, H
    Khachatryan, N
    Kliesckova, J
    Khan, AJ
    Khan, M
    Khan, P
    Kotrikadze, T
    Lachenal, N
    Lecca, L
    Lenggogeni, P
    Maretbayeva, S
    Melikyan, N
    Mesic, A
    Mitnick, CD
    Mofolo, M
    Perrin, C
    Richard, M
    Tassew, YM
    Telnov, A
    Vilbrun, SC
    Wanjala, S
    Rich, ML
    Hewison, C
    Show allShow less
    Issue Date
    2020-10-01
    Submitted date
    2020-12-03
    
    Metadata
    Show full item record
    Journal
    The International Journal of Tuberculosis and Lung Disease
    Abstract
    n 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major implementation challenges encountered in 17 endTB countries. We provide insights on how national TB programmes and other stakeholders can scale-up the programmatic use of new and repurposed TB drugs, while building scientific evidence about their safety and efficacy. For any new drug or diagnostic, multiple market barriers can slow the pace of scale-up. During 2015–2019, endTB was successful in increasing the number of patients receiving new and repurposed TB drugs in 17 countries. The endTB experience has many lessons, which are relevant to country level introduction of new TB drugs, as well as non-TB drugs and diagnostics. For example: the importation of TB drugs is possible even in the absence of registration; emphasis on good clinical monitoring is more important than pharmacovigilance reporting; national guidelines and expert committees can both facilitate and hinder innovative practice; clinicians use new and repurposed TB drugs when they are available; data collection to generate scientific evidence requires financial and human resources; pilot projects can drive national scale-up.
    Publisher
    International Union Against Tuberculosis and Lung Disease
    URI
    http://hdl.handle.net/10144/619795
    Language
    en
    Collections
    TB

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.